Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galnobax in diabetic foot ulcer
NCT01113515Phase 2Completed
- Sponsor
- NovaLead Pharma
- Start
- Feb 2014
- Primary completion
- Jun 2015
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of Galnobax in diabetic foot ulcer (DFU) (4 arms), sponsored by NovaLead Pharma. Primary endpoint: Safety Outcome at Week 25. Started Feb 2014; status: completed.
02
Drugs
Galnobax
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT01113515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01113515.